Healthcare and pharmaceutical services group United Drug has said it expects to record double-digit percentage growth in profits and earnings for the year to the end of September, despite the fall in the value of sterling.
Sterling's weakness reduces the value of profits the company earns from its UK and US operations.
In a trading statement covering its third financial quarter to the end of June, United said it experienced 'good trading conditions'. It said its performance was well ahead of the same period last year and in line with expectations.
United also said it had now completed its acquisition of US drug packaging company Sharp Corporation after receiving regulatory approval.
